Clinical trial • Phase IV • Other
Misoprostol for Uterine fibroid
Phase IV trial of Misoprostol for Uterine fibroid.
Overview
- Trial Therapeutic Area
- Other
- Trial Disease
- Uterine fibroid
- Trial Stage
- Phase IV
- Drug Modality
- Small molecule
Key dates
- Initial CTIS Submission Date
- 24-09-2024
- First CTIS Authorization Date
- 19-12-2024
Trial design
Randomised, placebo (oral coated tablet) versus misoone (misoprostol) 400 µg oral tablet (single pre-operative dose as per product specification).-controlled Phase IV trial across 1 site in France.
- Randomised
- Yes
- Comparator
- Placebo (oral coated tablet) versus MisoOne (misoprostol) 400 µg oral tablet (single pre-operative dose as per product specification).
- Target Sample Size
- 80
- Trial Duration For Participant
- 30
Eligibility
Recruits 80 No vulnerable population selected; participants are adult females aged 18 to 43. Subject information and informed consent form documents are available (SIS-and-ICF). No specific assent procedures or other vulnerable-population consent arrangements are described..
- Pregnancy Exclusion
- Pregnancy, suspected ectopic pregnancy and breastfeeding women.
- Vulnerable Population
- No vulnerable population selected; participants are adult females aged 18 to 43. Subject information and informed consent form documents are available (SIS-and-ICF). No specific assent procedures or other vulnerable-population consent arrangements are described.
Inclusion criteria
- {"criterion_text":"- Patient aged 18 to 43"}
- {"criterion_text":"- Symptomatic myomas (hemorrhages, pain or infertility)"}
- {"criterion_text":"- Indication for myomectomy by laparoscopy Fibroid ≤ 10cm or number ≤ 4 fibroids"}
- {"criterion_text":"- Indication for myomectomy by laparotomy Fibroid > 10cm, Number > 4 fibroids"}
- {"criterion_text":"- OTAU possible intraoperatively (Clip on uterine artery and Placement of a turnstile)"}
Exclusion criteria
- {"criterion_text":"- History of major uterine surgery or myomectomy (excluding myomectomy by hysteroscopy)"}
- {"criterion_text":"- Allergy to misoprostol"}
- {"criterion_text":"- Patient on aspirin or anticoagulant"}
- {"criterion_text":"- Patients with a hemostasis disorder"}
- {"criterion_text":"- Patient with hypersensitivity to misoprostol and/or other prostaglandins or to any of the excipients of the product"}
- {"criterion_text":"- Malnourished patients"}
- {"criterion_text":"- Patients with hepatic or renal impairment"}
- {"criterion_text":"- Pregnancy, suspected ectopic pregnancy and breastfeeding women."}
Endpoints
Primary endpoints
- {"endpoint_text":"- Intraoperative blood loss measured in mL (volume in the suction and blood volumes in the compresses after weighing) according to the randomization group.","definition_or_measurement_approach":"Measured in mL: volume in suction plus blood volumes in compresses after weighing, compared by randomization group."}
Secondary endpoints
- {"endpoint_text":"- Depending on the randomization group, compare the difference in hemoglobin pre- and post-operatively then at 1 month and hemoglobin level","definition_or_measurement_approach":"Difference in hemoglobin measured pre-operatively, post-operatively and at 1 month; comparison between randomization groups."}
- {"endpoint_text":"- Depending on the randomization group, compare: Demographic characteristics of patients and fibroids: BMI, Age, Gesture, Parity, Ethnicity, Tobacco, Taking pre-operative hormonal treatment, Type of treatment.","definition_or_measurement_approach":"Collection and comparison of demographic and clinical variables (BMI, age, gravidity, parity, ethnicity, tobacco use, pre-op hormonal treatment, treatment type) by randomization group."}
- {"endpoint_text":"- Depending on the randomization group, compare: Characteristics of myomas: Types of myomas (FIGO), Size of myomas, Number of myomas.","definition_or_measurement_approach":"Assessment and comparison of myoma characteristics (FIGO type, size, number) between groups."}
- {"endpoint_text":"- Depending on the randomization group, compare the duration between taking the tablet and anesthetic induction then the incision","definition_or_measurement_approach":"Time interval (tablet intake to anesthetic induction and to incision) recorded and compared between groups."}
- {"endpoint_text":"- Depending on the randomization group, compare the duration between incision or pneumoperitoneum and closure","definition_or_measurement_approach":"Operative time measured from incision or pneumoperitoneum start to closure; compared between groups."}
- {"endpoint_text":"- Depending on the randomization group, compare the accounting for the number of RGCs transfused.","definition_or_measurement_approach":"Number of red blood cell concentrates (RGCs) transfused recorded and compared between groups."}
- {"endpoint_text":"- Depending on the randomization group, compare the collection of early postoperative complications.","definition_or_measurement_approach":"Recording of early postoperative complications and comparison between groups."}
- {"endpoint_text":"- Depending on the randomization group, compare : EVA at H+2, H+6 D1 M1.","definition_or_measurement_approach":"Pain (EVA/VAS) measured at H+2, H+6, Day 1 and Month 1 and compared between groups."}
- {"endpoint_text":"- Depending on the randomization group, compare : Length of hospitalization in days.","definition_or_measurement_approach":"Length of hospital stay in days recorded and compared between groups."}
- {"endpoint_text":"- Depending on the type of surgery compare the difference in hemoglobin pre- and post-operatively then at 1 month and hemoglobin level","definition_or_measurement_approach":"Difference in hemoglobin measured pre-op, post-op and at 1 month, compared according to surgical technique (laparoscopy vs laparotomy)."}
- {"endpoint_text":"- Depending on the type of surgery compare the demographic characteristics of patients and fibroids: BMI, Age, Gesture, Parity, Ethnicity, Tobacco, Taking pre-operative hormonal treatment, Type of treatment.","definition_or_measurement_approach":"Demographic and clinical variables collected and compared by surgical technique."}
- {"endpoint_text":"- Depending on the type of surgery compare the characteristics of myomas: Types of myomas (FIGO), Size of myomas, Number of myomas.","definition_or_measurement_approach":"Myoma characteristics (FIGO type, size, number) assessed and compared by surgical technique."}
- {"endpoint_text":"- Depending on the type of surgery compare the duration between taking the tablet and anesthetic induction then the incision","definition_or_measurement_approach":"Time from tablet intake to anesthetic induction and incision measured and compared by surgical technique."}
- {"endpoint_text":"- Depending on the type of surgery compare the duration between incision or pneumoperitoneum and closure.","definition_or_measurement_approach":"Operative time (incision/pneumoperitoneum to closure) measured and compared by surgical technique."}
- {"endpoint_text":"- Depending on the type of surgery compare the accounting for the number of RGCs transfused.","definition_or_measurement_approach":"Number of RGCs transfused recorded and compared by surgical technique."}
- {"endpoint_text":"- Depending on the type of surgery compare the collection of early postoperative complications.","definition_or_measurement_approach":"Early postoperative complications collected and compared by surgical technique."}
- {"endpoint_text":"- Depending on the type of surgery compare EVA at H+2, H+6 D1 M1","definition_or_measurement_approach":"EVA/VAS pain scores at H+2, H+6, Day 1 and Month 1 compared by surgical technique."}
- {"endpoint_text":"- Depending on the type of surgery compare the length of hospitalization in days.","definition_or_measurement_approach":"Length of hospital stay in days compared by surgical technique."}
- {"endpoint_text":"- Intraoperative blood loss measured in mL (volume in aspiration and blood volumes in compresses after weighing) according to the randomization group and surgical technique.","definition_or_measurement_approach":"Measured intraoperative blood loss in mL (suction volume + blood in compresses after weighing) compared by randomization group and by surgical technique."}
Recruitment
- Planned Sample Size
- 80
- Recruitment Window Months
- 26
- Consent Approach
- Informed consent is obtained using Subject Information and Informed Consent Form documents (SIS-and-ICF) uploaded for the trial. Participants are adult females who provide their own consent. No specific languages, assent procedures, or remote consent processes are described in the available records.
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 80
France
- Earliest CTIS Part Ii Submission Date
- 07-11-2024
- Latest Decision Or Authorization Date
- 05-06-2025
- Processing Time Days
- 210
- Number Of Sites
- 1
- Number Of Participants
- 80
Sites
- Site Name
- University Hospital Of Clermont-Ferrand
- Department Name
- Gynecologie Obstétrique
- Contact Person Name
- Anne-Sophie GREMEAU
- Contact Person Email
- asgremeau@chu-clermontferrand.fr
- Number Of Participants
- 80
Sponsor
Primary sponsor
- Full Name
- University Hospital Of Clermont-Ferrand
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- France
Investigational products
- Investigational Product Name
- MisoOne 400 mikrogramų tabletės
- Active Substance
- Misoprostol
- Modality
- Small molecule
- Routes Of Administration
- ORAL
- Route
- ORAL
- Authorisation Status
- Marketing authorisation present (marketingAuthNumber: LT/1/22/5077/003)
- Starting Dose
- 400 Aµg
- Dose Levels
- 400 Aµg
- Maximum Dose
- 400 Aµg
- Investigational Product Name
- PLACEBO
- Active Substance
- PLACEBO
- Modality
- Small molecule
- Routes Of Administration
- ORAL
- Route
- ORAL
- Authorisation Status
- No marketing authorisation number specified
- Starting Dose
- 0 mg
- Dose Levels
- 0 mg
- Maximum Dose
- 0 mg
Related trials
Other published trials that may interest you.